ERIRIP SR 400 – Flupirtine SR 400mg Tablets
Flupirtine sits outside both major analgesic classes. It is not an NSAID, so it does not carry the gastric and renal burden that limits diclofenac and aceclofenac in older or comorbid patients, and it is not an opioid, so it avoids that dependence profile entirely. The sustained-release format at 400mg allows once-daily administration where immediate-release Flupirtine requires dosing several times a day.
Product Specifications
Brand Name: ERIRIP SR 400
Generic Name: Flupirtine Maleate
Strength: 400 mg (Sustained Release)
Dosage Form: Sustained Release Tablet
Therapeutic Category: Analgesics, Ortho and Pain Management
Prescription Status: Schedule H
Storage: Store below 25°C, protect from light and moisture
Composition
Flupirtine Maleate — equivalent to Flupirtine 400 mg (Sustained Release) — Centrally acting non-opioid analgesic; opens neuronal potassium channels to stabilise resting membrane potential
Mechanism of Action
Flupirtine opens G-protein-coupled inwardly rectifying potassium channels in neurons, stabilising the resting membrane potential so those neurons are less likely to depolarise in response to incoming pain signals. This indirectly blocks NMDA receptor activation, a pathway through which pain signalling becomes amplified and self-sustaining over time. The same membrane-stabilising action on motor neurons produces a muscle-relaxant effect, so the molecule addresses both nociceptive input and the accompanying spasm within a single mechanism rather than through separate components.
The sustained-release matrix alters delivery rather than mechanism. Gradual release across the dosing interval maintains plasma concentrations within a narrower band than the peak-and-trough profile of immediate-release dosing, supporting once-daily administration.
Clinical Applications
- Acute musculoskeletal and low back pain
- Pain presentations with an accompanying muscle spasm component
- Post-operative and post-traumatic pain
- Pain management in patients where NSAIDs are contraindicated on gastric or renal grounds
- Neuropathic and nerve-related pain, under physician assessment
Prescriber Profile
Orthopedicians represent the primary prescribing base, particularly in back pain and musculoskeletal presentations where spasm is a contributing factor and a once-daily regimen supports adherence. Neurologists prescribe it across nerve-related pain presentations. Pain specialists, general physicians and hospital-based prescribers account for secondary use, largely in NSAID-intolerant patients.
Dosage and Administration
As prescribed by a Registered Medical Practitioner. Sustained-release tablets are swallowed whole and must not be crushed, split or chewed, as this releases the full dose immediately and alters the intended exposure profile. Flupirtine is indicated for short-term use, with treatment duration limited to the shortest period clinically necessary. This is a Schedule H drug — sale by retail is permitted only against the prescription of a Registered Medical Practitioner.
Safety Information
Flupirtine carries a recognised risk of hepatic injury, and this governs its clinical use. Liver function should be assessed before initiation and monitored during therapy as directed by the prescribing physician, with treatment restricted to short courses rather than continued long-term. It is not indicated in patients with pre-existing hepatic disease, a history of alcohol dependence, or on concurrent hepatotoxic medication. Jaundice, dark urine, persistent nausea, upper abdominal discomfort or unusual fatigue during treatment warrants immediate medical review and discontinuation under physician guidance. Drowsiness may occur; caution is advised with driving or operating machinery. Store below 25°C, protect from light and moisture. Keep out of reach of children.
Range Positioning
ERIRIP SR 400 completes the Flupirtine strength ladder alongside ERIRIP 100, covering both immediate-release and once-daily sustained-release presentations within the Eridanus Healthcare ortho and pain range. This allows a prescriber to move a patient between formats without changing brand.
PCD Pharma Franchise Availability
ERIRIP SR 400 is available for PCD Pharma Franchise across India. Territory rights are allotted on a monopoly basis subject to availability, and franchise partners receive promotional inputs and product literature across the ortho and pain range.
Frequently Asked Questions
How does Flupirtine differ from NSAIDs and opioids?
Flupirtine belongs to neither class. It acts by opening neuronal potassium channels rather than inhibiting prostaglandin synthesis or binding opioid receptors, avoiding the gastric and renal considerations of NSAIDs and the dependence profile of opioids.
What distinguishes ERIRIP SR 400 from ERIRIP 100?
ERIRIP 100 is an immediate-release presentation typically dosed several times daily. ERIRIP SR 400 releases gradually across the dosing interval, supporting once-daily administration with a steadier plasma profile.
Can the sustained-release tablet be split or crushed?
No. Splitting or crushing releases the full dose at once, removing the benefit of controlled release and altering intended exposure.
Does Flupirtine require liver function monitoring?
Yes. Given the recognised risk of hepatic injury, liver function assessment before and during treatment is advised, with use restricted to short courses under physician supervision.
Why does Flupirtine also relieve muscle spasm?
The same membrane-stabilising effect that reduces pain signalling acts on motor neurons, producing muscle relaxation alongside analgesia.
Is ERIRIP SR 400 available for PCD Pharma Franchise in India?
Yes. ERIRIP SR 400 is available for PCD Pharma Franchise across India under Eridanus Healthcare, with monopoly-basis territory rights subject to availability.
Which prescribers form the target base for Flupirtine SR 400mg in a PCD Pharma Franchise range?
Orthopedicians and neurologists are the primary prescribers, with pain specialists and general physicians as secondary coverage — relevant for franchise partners building an ortho and pain portfolio.
How can a distributor apply for PCD Pharma Franchise rights for ERIRIP SR 400?
Distributors and pharmaceutical professionals holding a valid Drug Licence and GST registration may contact Eridanus Healthcare to discuss territory availability and franchise terms.
This page is intended for pharmaceutical distributors, wholesalers, and healthcare professionals. Product information is provided for commercial and educational reference and is not a substitute for professional medical advice. Eridanus Healthcare does not sell directly to patients. This is a Schedule H drug — to be sold by retail only on the prescription of a Registered Medical Practitioner. Flupirtine requires liver function monitoring and short-duration use under medical supervision. All trade enquiries are subject to valid Drug Licence and GST verification.